D.E. Shaw & Co
INZY

D.E. Shaw & Co’s Inozyme Pharma INZY Stock Holding History

D.E. Shaw & Co’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-53,381
Closed -$48.6K – 4515
2025
Q1 		$48.6K Buy
53,381
+35,568
+200% +$49.3K ﹤0.01% 4063
2024
Q4 		$49.3K Buy
+17,813
New +$67.8K ﹤0.01% 4201
2021
Q1 		– Sell
-12,016
Closed -$248K – 4259
2020
Q4 		$248K Buy
+12,016
New +$286K ﹤0.01% 3663

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

D.E. Shaw & Co's INZY Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 53,381 shares — an estimated $48.6K sold.

D.E. Shaw & Co first reported a position in INZY in Q4 2020 and held it in 3 quarters. The position peaked at $248K in Q4 2020. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 53,381 Inozyme Pharma shares in Q2 2025, an estimated $48.6K.
  • D.E. Shaw & Co first reported a position in Inozyme Pharma in Q4 2020 and held it in 3 quarters.
  • D.E. Shaw & Co's Inozyme Pharma position peaked at $248K in Q4 2020.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.